Clinical Trial Update: Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating neoadjuvant abemaciclib with fulvestrant in ER/PR positive, HER2-negative breast cancer has been terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasm
• Hormone Receptor Positive Breast Carcinoma

Drugs mentioned

• Abemaciclib (abemaciclib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: University of California, Irvine | Conditions: Breast Neoplasm, Hormone Receptor Positive Breast Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2023-03-03